914 results on '"Åsberg, Anders"'
Search Results
52. The Authors’ Reply
53. A Limited Sampling Strategy to Estimate Exposure of Everolimus in Whole Blood and Peripheral Blood Mononuclear Cells in Renal Transplant Recipients Using Population Pharmacokinetic Modeling and Bayesian Estimators
54. #3641 DOES IBANDRONATE OR CALCIUM AND VITAMIN D MAINTAIN OR IMPROVE BONE MICROARCHITECTURE IN THE FIRST YEAR AFTER KIDNEY TRANSPLANTATION?
55. The ERA Registry Annual Report 2020: a summary
56. Severe Mycophenolate Intoxication in a Solid Organ Transplant Recipient—No Intervention Actually Needed
57. Plasma Levels of Marine n-3 Fatty Acids Are Inversely Correlated With Proinflammatory Markers sTNFR1 and IL-6 in Renal Transplant Recipients
58. Validation of diagnostic utility of fasting plasma glucose and HbA1c in stable renal transplant recipients one year after transplantation
59. The Authors’ Reply: Placental Pathology in Pregnancies After Kidney Transplantation
60. Tacrolimus Area Under the Concentration Versus Time Curve Monitoring, Using Home-Based Volumetric Absorptive Capillary Microsampling
61. Immunosuppression and Reproductive Health After Kidney Transplantation
62. Tacrolimus Can Be Reliably Measured With Volumetric Absorptive Capillary Microsampling Throughout the Dose Interval in Renal Transplant Recipients
63. Measuring senescence rates of patients with end-stage renal disease while accounting for population heterogeneity: an analysis of data from the ERA-EDTA Registry
64. A Method for Evaluating Robustness of Limited Sampling Strategies—Exemplified by Serum Iohexol Clearance for Determination of Measured Glomerular Filtration Rate
65. Glycated albumin and post-transplant diabetes mellitus in kidney transplant recipients
66. Trends in kidney transplantation rate across Europe: study from the ERA Registry
67. Plasma n-3 Polyunsaturated Fatty Acids and Bone Mineral Density in Renal Transplant Recipients
68. Lessons Learned From a Randomized Study of Oral Valganciclovir Versus Parenteral Ganciclovir Treatment of Cytomegalovirus Disease in Solid Organ Transplant Recipients: The VICTOR Trial
69. Therapeutic Drug Monitoring of Tacrolimus-Personalized Therapy: Second Consensus Report
70. A Fully Automated Method for the Determination of Serum Belatacept and Its Application in a Pharmacokinetic Investigation in Renal Transplant Recipients
71. The HUNT4 study: the validity of questionnaire-based diagnoses
72. A rapid and sustained improvement of calcification propensity score (serum T50) after successful kidney transplantation: Reanalysis of a randomized controlled trial of ibandronate
73. Kidney-transplanted Adolescents—Nonadherence and Graft Outcomes During the Transition Phase: A Nationwide Analysis, 2000–2020
74. Fourth dose of the SARS-CoV-2 vaccine in kidney transplant recipients with previously impaired humoral antibody response
75. COVID-19-related mortality in kidney transplant and haemodialysis patients
76. Sex differences in COVID-19 mortality risk in patients on kidney function replacement therapy
77. Impact of type 2 diabetes on in vivo activities and protein expressions of cytochrome P450 in patients with obesity
78. Titers of antibodies the receptor-binding domain (RBD) of ancestral SARS-CoV-2 are predictive for levels of neutralizing antibodies to multiple variants
79. Kidney biopsy diagnosis in childhood in the Norwegian Kidney Biopsy Registry and the long-term risk of kidney replacement therapy: a 25-year follow-up
80. Visceral fat is strongly associated with post‐transplant diabetes mellitus and glucose metabolism 1 year after kidney transplantation
81. Preserved Insulin Sensitivity and Kidney Function One Year After Successful Pancreas Transplantation
82. Use of Empagliflozin in Renal Transplant Recipients with Post Transplantation Diabetes Mellitus: Short Term Safety
83. Determination of Tacrolimus Concentration and Protein Expression of P-glycoprotein in Single Human Renal Core Biopsies
84. High-Dose Fish Oil Supplementation Increase Tacrolimus Exposure in Stable Renal Transplant Recipients
85. High Tacrolimus Clearance – A Risk Factor for Development of Interstitial Fibrosis and Tubular Atrophy in the Transplanted Kidney
86. Adherence to Immunosuppressive Medications in Renal Transplant Recipients – Different Tools Capture Different Patients
87. A Limited Sampling Strategy to Estimate Whole Blood and Intra-lymphocyte Exposure of Everolimus in Renal Transplant Recipients using Population Pharmacokinetic Modeling and Bayesian Estimators
88. Outcomes of Kidney Transplantation in Former Non Kidney Solid Organ Transplant
89. A Simple Strategy for Diagnosis of PTDM in Stable Kidney Transplanted Patients
90. First Scandinavian Protocol for Controlled Donation After Circulatory Death Using Normothermic Regional Perfusion
91. The Authors’ Reply
92. Estimating Glomerular Filtration Rate in Kidney Transplant Recipients: Comparing a Novel Equation With Commonly Used Equations in this Population
93. Haptoglobin 2-2 Genotype, Patient, and Graft Survival in Renal Transplant Recipients
94. How to Report and Interpret Bioequivalence Data in Solid Organ Transplant Recipients
95. Paricalcitol supplementation during the first year after kidney transplantation does not affect calcification propensity score
96. The epidemiology of headache disorders: a face-to-face interview of participants in HUNT4
97. Clinical, Functional, and Mental Health Outcomes in Kidney Transplant Recipients 3 Months After a Diagnosis of COVID-19
98. Anticoagulation and safety of renal transplant biopsy
99. Demonstrating Benefit-Risk Profiles of Novel Therapeutic Strategies in Kidney Transplantation: Opportunities and Challenges of Real-World Evidence
100. FC 111: A Comorbidity Index and Pretransplant Physical Status Predict Survival in Older Kidney Transplant Recipients
Catalog
Books, media, physical & digital resources
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.